Ozempic, Mounjaro, Wegovy: Complete Guide to Side Effects

1. The right framework

A side effects report should be read with two questions, never just one: what frequency, and what severity. Nausea affects a large share of patients and sends almost no one to the hospital; pancreatitis is serious and concerns a tiny minority; muscle loss causes no acute symptoms and affects everyone a little. Confusing these categories produces the two symmetrical errors that saturate the debate: panic ("this treatment destroys the pancreas") and denial ("just some nausea, nothing more").

One metric sums up better than anything else the real weight of tolerability: in SELECT, the largest trial ever conducted with semaglutide 2.4 mg (17,604 patients followed for over 3 years), 16.6% of participants under treatment permanently stopped due to adverse effects, versus 8.2% under placebo. One in six patients, under ideal trial conditions: that's the true "average cost," before even discussing rare events.

2. Digestive issues: the entry toll

The very mechanism of treatment, slowing the stomach and cutting hunger, comes at the cost of digestive discomfort: in STEP 1 as in SURMOUNT-1, nausea, vomiting, diarrhea and constipation overwhelmingly dominate the picture, especially during theprogressive dose escalation, with generally mild to moderate intensity and a clear tendency to decrease over time. Added to these, depending on the patient: reflux, belching, fatigue in the first weeks, and transient hair loss that stems from the speed of weight loss itself (hair dislikes sudden deficits) more than from the molecule.

Two practical messages. First, these symptoms can be managed, with the prescriber : adapted dose escalation pace, smaller and divided meals, limiting high-fat meals, serious hydration; patients who suffer in silence are the ones who give up. Next, two red flags amid the ordinary: persistent vomiting that prevents hydration, and any severe abdominal pain, which no longer fall within expected discomfort but warrant immediate medical attention (following sections).

3. The gallbladder: the price of speed

This is the chapter that best validates the intuition "you don't lose weight this fast for free," and it deserves to be understood rather than feared. Biliary risk is not a quirk of the molecule: any rapid weight loss massively mobilizes cholesterol, saturates bile and promotes gallstones, a well-known phenomenon after bariatric surgery or very restrictive dieting. GLP-1s add their own touch by slowing gallbladder emptying, which stagnates and concentrates. Speed plus stasis: the conditions for stone formation are met, and the dose-duration effect observed in the meta-analysis confirms the mechanism.

In practice: most gallstones will remain silent, but severe pain under the right rib cage, typically in the hours following a meal, with or without fever, requires prompt consultation; this is the picture of biliary colic or cholecystitis, which is treated all the better for being caught early.

4. Rare but serious: pancreas, eye, thyroid

The pancreas and intestine. A pharmacovigilance study published in JAMA (Sodhi et al., 2023) finds, in GLP-1 users for weight loss compared to users of another weight-loss medication, an association with acute pancreatitis, gastroparesis (an almost stopped stomach, with persistent vomiting) andbowel obstruction. Absolute incidences remain low, but the course of action is non-negotiable: severe abdominal pain, especially radiating to the back, or uncontrollable vomiting equal immediate medical attention.

The eye. NAION, a sudden, painless and generally permanent vision loss in one eye, made headlines after the Boston cohort (Hathaway et al., JAMA Ophthalmology 2024): risk multiplied by 4.3 in diabetics and 7.6 in overweight patients on semaglutide. Honest reading required: the cohort comes from a specialized neuro-ophthalmology consultation, a major recruitment bias that the authors acknowledge by declining to conclude causality, and regulatory agencies classify the event among the effects very rare. The key principle to remember is this: any sudden vision loss in one eye is an ophthalmic emergency, whether under treatment or not.

The thyroid. The French study based on health insurance data (Bezin et al., Diabetes Care 2023) found thyroid cancer risk multiplied by approximately 1.6, and by 1.8 for medullary cancer, after 1 to 3 years of use; other analyses do not confirm this, and the scientific debate remains open. The practical rule, however, is already established: contraindication in case of personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, and any cervical nodule that appears should be reported to the physician.

5. The silent cost: muscle and nutrient deficiencies

This is the most universal and most neglected cost item, because it produces no acute symptoms : no one consults for three kilos of lost muscle. It is paid for later, in slowed metabolism (muscle is the body's primary calorie consumer; losing it sets the stage for weight regain), in strength and function, and in a "melted" rather than refined silhouette. The mechanism is straightforward: when appetite collapses, proteins and micronutrients collapse with it, unless there is deliberate and organized intervention.

The countermeasure is the only part of this issue where everyone has control: aim for 1.2 to 1.6 g of protein per kilogram per day, distributed across each meal rather than all at once, add muscle strengthening 2 to 3 times per week (the signal that tells the body to preserve muscle), and follow up with your care team on targeted micronutritional assessment : vitamin D, B12, iron, folates, zinc. With reduced appetite, meeting these targets through food alone becomes a real logistical challenge; this is exactly the type of situation where supplementation warrants discussion with your care team, never in its place.

6. What science has not confirmed

The alert on suicidal ideation, arising from pharmacovigilance reports in 2023, triggered exactly what it should have: regulatory investigations and large studies. The result is remarkably clear: not only is the increased risk not confirmed, but the observed association goes in the opposite direction, and European agencies have not established a causal link. Individual vigilance regarding mental health during any major body transformation remains warranted; the specific concern, however, does not hold up.

And to weigh the complete picture, the benefits column exists too: beyond weight loss, the SELECT trial showed in 17,604 cardiovascular patients a 20% reduction in major events (cardiovascular death, myocardial infarction, stroke). This is what makes these treatments a genuine medical transaction: real costs on one side, real benefits on the other, and a balance that is only seriously calculated for a given patient, with their physician.

7. Your situation, the right course of action

Frequently asked questions about GLP-1 side effects

Learn more